33 related articles for article (PubMed ID: 38408288)
1. Tolerability of Daratumumab Amongst Asian Patients with Plasma Cell Dyscrasias - A Single Centre Experience.
Tso ACY; Wang SSY; Gallardo CA; Christopher D; Ong KH
Clin Hematol Int; 2024; 6(1):16-22. PubMed ID: 38817701
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab.
Moore DC; Arnall JR; Thompson DL; Martin AL; Robinson J; Ndiaye A; Paul B; Atrash S; Bhutani M; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e777-e781. PubMed ID: 32660902
[TBL] [Abstract][Full Text] [Related]
3. Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice.
Hamadeh IS; Moore DC; Martin A; Karabinos A; Hill H; Ndiaye A; Robinson JD; Paul BA; Atrash S; Bhutani M; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):470-475. PubMed ID: 33785299
[TBL] [Abstract][Full Text] [Related]
4. 'Fast but not so Furious': Short observation time after subcutaneous Daratumumab administration is both a safe and cost-effective strategy.
Davis JA; Youngberg H; Gaffney K; Duco M; Hashmi H
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e680-e684. PubMed ID: 35414476
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Mateos MV; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis N; Flogegard M; Bladé J; Moreau P; Kaiser M; Iida S; Laubach J; Magen H; Cavo M; Hulin C; White D; De Stefano V; Clemens PL; Masterson T; Lantz K; O'Rourke L; Heuck C; Qin X; Parasrampuria DA; Yuan Z; Xu S; Qi M; Usmani SZ
Lancet Haematol; 2020 May; 7(5):e370-e380. PubMed ID: 32213342
[TBL] [Abstract][Full Text] [Related]
6. Successful use of split-dose intravenous daratumumab in a multiple myeloma patient after a first-dose life-threatening infusion-related reaction.
Aykaş F; Karakuş V; Sevindik ÖG
J Oncol Pharm Pract; 2024 Mar; 30(2):397-399. PubMed ID: 37990526
[TBL] [Abstract][Full Text] [Related]
7. Impact of Premedication De-Escalation on Incidence of Infusion-Related Reactions With Daratumumab.
Vazirnia D; Del Rio Verduzco A; Soefje SA; Sanders KA; Sandahl TB
JCO Oncol Pract; 2024 Feb; ():OP2300470. PubMed ID: 38408288
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis.
Hughes MS; Lentzsch S
Ther Clin Risk Manag; 2023; 19():1063-1074. PubMed ID: 38164204
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma.
Sanchez L; Richter J; Cho HJ; Jagannath S; Madduri D; Parekh S; Richard S; Tam L; Verina D; Chari A
Ther Adv Hematol; 2021; 12():2040620720987075. PubMed ID: 33613930
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma.
Paul B; Atrash S; Bhutani M; Voorhees P; Hamadeh I; Usmani SZ
Expert Rev Hematol; 2020 Aug; 13(8):795-802. PubMed ID: 32659139
[TBL] [Abstract][Full Text] [Related]
11. Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab.
Nooka AK; Gleason C; Sargeant MO; Walker M; Watson M; Panjic EH; Lonial S
J Oncol Pract; 2018 Jul; 14(7):414-422. PubMed ID: 29996069
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]